Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Document › Details

Babraham Research Campus (Babraham Bioscience Technologies Ltd.). (10/10/12). "Press Release: Babraham Research Campus, Neusentis (Pfizer) and Medimmune (AstraZeneca) Announce Initative in Open-innovation". Cambridge.

Region Region Cambridge, Cambridgeshire
  Country United Kingdom (GB)
Organisations Organisation Babraham Bioscience Technologies Ltd. (Babraham Research Campus)
  Group Babraham Institute
  Organisation 2 MedImmune (biologics division of AstraZeneca)
  Group AstraZeneca (Group)
Products Product drug discovery
  Product 2 business development (state/region)
Person Person Jones, Derek (Babraham Bioscience Technologies Ltd 201210 CEO)
     


Three leading Cambridge based organisations today reaffirmed their commitment to the open-innovation agenda through a new initiative at the heart of the Cambridge Bioscience cluster. The new collaboration aims to identify new therapeutic treatments, with the premise that early-stage collaboration maximises success.

The three organisations are: the Babraham Research Campus - home to both the Babraham Institute and 35 early stage biomedical enterprises within its Bioincubator; Neusentis - a division of Pfizer; and MedImmune - the biologics arm of Astra Zeneca.

The aim of greater co-operation and 'open innovation' between the parties is to increase the flow of knowledge, to identify opportunities and to reduce barriers to early-stage discussions. Neusentis and MedImmune, although not located on the campus, are a key part of the Babraham Research Campus community, attending lectures, sharing access to expertise and campus infrastructure, as well as being welcomed to campus events. Neusentis and MedImmune benefit from the early-stage interactions with the academic community and the companies located at the campus. Both Neusentis and MedImmune in return are committed to opening up their organisations, providing the Babraham Research Campus community with opportunities to access resources, skills and technologies that are not available at the campus.

Derek Jones, CEO Babraham Bioscience Technologies, with responsibility for the bio-incubator facilities at the campus said, "We have always had a good working relationship with both Neusentis and MedImmune, which being located at Granta Park are our close neighbours. We realised there was more that we could do together to encourage interactions; not being located on the campus should not be a barrier to working closely with the vibrant ecosystem at Babraham. Our approach is that the infrastructure, capabilities and resources we have created here should be available to the wider community. I am greatly encouraged by the approach Neusentis and MedImmune have articulated. I look forward to being able to announce specific initiatives and projects centred on these relationships."

Jane Osbourn, Cambridge Site Lead and Vice President of R&D for MedImmune said, "The Babraham Research Campus is a fantastic source of knowledge, ideas and expertise on our doorstep. The building of more open and interactive relationships with Babraham and Neusentis scientists through this initiative can only serve to expedite scientific information and skill exchange, together with collaboration and idea generation across our joint communities. MedImmune is very excited by the opportunity created by this open-innovation initiative and we're committed to help drive it forward."

Dr Ruth McKernan, Senior Vice President of Pfizer and Chief Scientific officer at Pfizer's Cambridge Research Unit, Neusentis added, "One of the great advantages of being in a biotech hub like Cambridge is that we can work closely with some of the most innovative groups in the world. I am looking forward to greater interaction with the scientists and companies at the Babraham Campus."


Contact details:

Dr Claire Cockcroft
Head, External Relations, The Babraham Institute
Email: claire.cockcroft@bbsrc.ac.uk
Tel: +44 (0)1223 496260
Mobile: +44 (0)7786 335978

Derek Jones,
Chief Executive, Babraham Bioscience Technologies Limited
Email: derek.jones@babraham.co.uk
Tel: +44 (0)1223 496262
Babraham Research Campus
Cambridge
CB22 3AT
United Kingdom

http://www.babraham.ac.uk and http://www.babraham.co.uk


Notes to Editors:


Babraham Bioscience Technologies Ltd.

Babraham Bioscience Technologies Ltd is the commercial arm of the Babraham Institute, an institute which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC) devoted to life sciences research. BBT promotes, supports and encourages academic and commercial biomedical research locally, regionally and nationally. BBT delivers the Knowledge Exchange remit of the Institute and is responsible for managing the Babraham Research Campus' Bioincubator, currently home to around 30 early-stage biomedical companies. BBT brings together all the elements to support innovation and enable the successful exploitation of research in the biomedical sector based on technologies emanating from the Babraham Institute and bioventures relocating to the campus. BBT has taken a prominent role regionally, initiating and leading partnerships to promote knowledge and skills flow and has established a reputation for successfully translating innovative science into viable business opportunities through partnerships for wealth creation. Website: www.babraham.com


The Babraham Institute

The Babraham Institute, which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC), undertakes international quality life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. The institute received £22.4M investment from BBSRC in 2010-11. The Institute's research provides greater understanding of the biological events that underlie the normal functions of cells and the implication of failure or abnormalities in these processes. Research focuses on signalling and genome regulation, particularly the interplay between the two and how epigenetic signals can influence important physiological adaptations during the lifespan of an organism. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and healthier ageing. (www.babraham.ac.uk)


About BBSRC

The Biotechnology and Biological Sciences Research Council (BBSRC) invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.

Funded by Government, and with an annual budget of around £445M, we support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.

For more information about BBSRC, our science and our impact see: www.bbsrc.ac.uk

For more information about BBSRC strategically funded institutes see: www.bbsrc.ac.uk/institutes

   
Record changed: 2018-01-29

Advertisement

Picture [iito] – Putting Information into Context 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top